Cardiac CT in ANOCA, INOCA, and MINOCA: a structured narrative review of evidence, applications, and limitations
Frontiers in Cardiovascular Medicine · 2026-11-11 · 13
DOI: 10.3389/fcvm.2026.1958677 ↗Abstract
Cardiac computed tomography (CT) depicts coronary anatomy and provides additional physiological and myocardial measurements in angina or ischemia with non-obstructive coronary arteries (ANOCA/INOCA) and acute non-obstructive presentations. This structured narrative review examines what these measurements establish about anatomy, vasomotor mechanisms, prognosis, and clinical utility. Six-domain searches of PubMed, Embase, and CENTRAL, supplemented by citation-based sources and ClinicalTrials.gov, were updated through 23 September 2026. The bibliographic inventory contains 154 publications; selection was targeted, involving single-assessor historical screening and revision-stage triage rather than a systematic-review process. Contemporary MINOCA denotes myocardial injury with non-obstructive coronary arteries as a working diagnosis; historical study definitions are preserved. Conventional coronary CT angiography depicts plaque, anomalies, myocardial bridging, and selected coronary-wall abnormalities. Plaque and pericoronary-fat associations vary with the population and reference standard. Small syndrome-specific studies and related cohorts provide limited diagnostic evidence; prognostic associations do not validate vasomotor endotyping. CT-derived fractional flow reserve concerns epicardial pressure loss, while CT perfusion does not independently identify a vasomotor mechanism. Late iodine enhancement and CT-derived extracellular volume provide myocardial information, but agreement with individual cardiovascular magnetic resonance (CMR) measurements does not establish equivalence to multiparametric CMR. After non-obstructive invasive angiography, additional CT should answer a defined residual question and justify contrast exposure, radiation, and diagnostic delay. The evidence examined in this review does not establish that an advanced CT biomarker strategy improves mechanism-specific treatment selection or patient outcomes in ANOCA/INOCA or an acute MINOCA pathway.
EUVIMED